Participated · Equity · Mar 2026

Founded in 2024 out of the University of Strasbourg, Albupad engineers a proprietary platform that stabilises native albumin to create drug-delivery systems capable of releasing biologic medicines over extended periods. The technology targets chronic illnesses and oncology indications where sustained dosing can improve efficacy and patient compliance. Albupad’s approach aims to integrate seamlessly into existing pharmaceutical pipelines, offering partners turn-key formulations rather than standalone drugs. The company estimates the addressable global market for long-acting biologics exceeds €400 billion. Proceeds from its latest raise will fund prototype development and advance regulatory preparations. Although still pre-revenue, Albupad is positioning itself as an enabling technology provider to large pharma and biotech firms.

Participated · Equity · Nov 2025

Founded in 2022 in Haguenau, Vaultys develops a cybersecurity platform that leverages decentralized cryptography to eliminate centralized credential storage and reduce the risk of large-scale data breaches. The solution targets enterprises that handle sensitive information and aims to restore trust by removing single points of failure. Vaultys is collaborating with the CEA-List research institute to advance fundamental work on decentralized cryptographic environments, with plans to establish a joint laboratory in 2027. Early 2026 will see the launch of the "Vaultys Box," an ultra-secure environment for storing critical data and providing a virtual crisis-management room with encrypted chat and video. The company currently employs five people and has recently added a business developer to accelerate commercial expansion. Adoption of decentralized cryptographic security remains limited across enterprises, but Vaultys believes awareness is growing. The startup has raised €600 000 to fund its go-to-market efforts and continue product development.

Participated · Equity · Jul 2024

Pass Intérim operates a matchmaking platform that connects intérimaires (temporary workers) with employment agencies. The company is based in the Vosges (Grand Est) region. It announced a fundraising round of €600,000. The round was supported by Alsace Business Angels, I‑Neo Capital and a private professional investor from the recruitment sector. The company says the funds will be used to pursue national expansion and to develop its R&D efforts. The article does not disclose any revenue, user counts, or other operating metrics.

Participated · Seed · May 2023

Odimma Therapeutics develops ODI-2001, a first-in-class personalized immunotherapy candidate for cancer. The company completed proof-of-activity experiments of ODI-2001 in several hard-to-treat preclinical cancer models and has secured the pharmaceutical process for production. Pharmaceutical partnerships support key components of the product: myNEO for neoepitope prediction by AI, Touchlight Genetics for synthetic DNA production, and ABL Europe for the viral component. Current activities focus on preparation of a Phase I First-in-Man clinical trial in patients with advanced solid tumors, including regulatory interactions, toxicology and clinical operations. R&D activities are being strengthened to generate additional data and intellectual property. The company recently raised financing to support these clinical preparations and is actively working on its next financing round.

Participated · Series A · Jan 2023

Miraxess develops Mirabook, a laptop-like passive terminal that receives operating-system commands from a user's smartphone and can optionally use a Mirabook-specific dock. The product is designed to let smartphones act as de facto computers for professionals on the move and to reduce the cyber-attack surface compared with adding a Windows-driven machine. Mirabook is reported to cut 56% of the emissions profile versus a traditional laptop. Miraxess has been marketing the device to English police forces and Irish customers and will begin contract-factory production in France sometime next year. Samsung has provided promotional support via its DeX technology. The company says it aims to become a major European B2C electronics name within ten years and is relocating its head office from Lyon to the Grand Est region to ease supply-chain links with manufacturing partner 2CRSI.